Inclusion Criteria:

- Age ≥ 18 years

- Histologically-proven ovarian cancer, fallopian tube and primary peritoneal cancer in
advanced or metastatic stage

- Patients previously treated with a maximum of two platinum-based regimen plus
paclitaxel and with documented progressive disease on treatment (refractory patient
population) or within 6 months from last chemotherapy cycle (resistant patient
population)

- Good clinical Conditions

- Normal cardiac function

- Adequate baseline bone marrow, hepatic and renal function

- At least one (not previously irradiated) target lesion or non-measurable disease
only, according to RECIST criteria

- Patients may have had prior therapy providing the following conditions are met:

- Surgery and radiation therapy: wash-out period of 14 days

- Systemic anti-tumor therapy: wash-out period of 21 days

Exclusion Criteria:

- Patients may not receive any other investigational agents while on study

- More than two previous chemotherapy lines and previous treatment with anthracycline

- Patients with myocardial infarction within the last six months, unstable angina, New
York Heart Association (NYHA) grade II or greater congestive heart failure, or
serious cardiac arrhythmia requiring medication

- Prolonged QTc interval (congenital or acquired) > 450 ms

- History or evidence upon physical examination of CNS disease unless adequately
treated

- Patients with active or uncontrolled systemic disease/infections or with serious
illness or medical conditions, which is incompatible with the protocol

- Known hypersensitivity/allergic reaction to human albumin preparations or to any of
the excipients

- Any psychological, familial, sociological or geographical condition potentially
hampering compliance with the study protocol

- Pregnancy or lactation.